Cision PR Newswire

Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy

NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...

MINISFORUM Launches MS-S1 MAX-P495 with 192GB Unified Memory, Expanding Its Local AI Computing Strategy

SHENZHEN, China, Oct. 8, 2026 /PRNewswire/ -- As Artificial Intelligence (AI) evolves toward Super...

Dongpeng Highlights Sustainable Procurement at UN Global Compact Leaders Summit

Supplier capability building and circular materials connect sustainability requirements with opportunities for collaboration ...

Lufax Announces Poll Results of Extraordinary General Meeting

SHANGHAI, Oct. 8, 2026 /PRNewswire/ -- Lufax Holding Ltd ("Lufax" or the "Company") (NYSE:...